Combination therapy with cerivastatin and nifedipine improves endothelial dysfunction after balloon injury in porcine coronary arteries

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 1, 2005, Pages 1-6

  Eto, Yasuhiro ^a   Shimokawa, Hiroaki ^a   Fukumoto, Yoshihiro ^a   Matsumoto, Yasuharu ^a   Morishige, Kunio ^a   Kunihiro, Ikuko ^a   Kandabashi, Tadashi ^a   Takeshita, Akira ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Balloon injury; Calcium channel blockers; Endothelium dependent relaxation; Statin

Indexed keywords

BRADYKININ; CALCIMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NIFEDIPINE; NITROPRUSSIDE SODIUM; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALLOON; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; ENZYME REGULATION; IN VITRO STUDY; LEFT CORONARY ARTERY; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE; VASCULAR ENDOTHELIUM; VASODILATATION; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; BALLOON DILATATION; BLOOD CHEMICAL ANALYSIS; BLOTTING, WESTERN; BRADYKININ; CALCIMYCIN; CORONARY ANGIOGRAPHY; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NIFEDIPINE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE III; NITROPRUSSIDE; PYRIDINES; SEROTONIN; SWINE; VASODILATION; VASODILATOR AGENTS;

EID: 21444435685     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000161404.99079.d2     Document Type: Article

References (37)

1. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 1999; 33:2092-2197.
2. Shimokawa H, Aarhus LL, Vanhoutte PM. Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin. Circ Res. 1987;61: 256-270.
3. Shimokawa H, Flavahan NA, Vanhoutte PM. Natural course of the impairment of endothelium-dependent relaxations after balloon endothelium removal in porcine coronary arteries. Possible dysfunction of a pertussis toxin-sensitive G protein. Circ Res. 1989;65:740-753.
4. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol. 1999;31:23-37.
5. Luscher TF. Vascular protection: current possibilities and future perspectives. Int J Clin Pract Suppl. 2001;117:3-6.
6. 4S Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
8. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
9. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric j oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97: 1129-1135.
10. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001;103: 276-283.
11. Fukumoto Y, Libby P, Rabkin E, et al. Stalins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 2001;103:993-999.
12. Ding Y, Vaziri ND. Nifedipine and diltiazem but not verapamil upregulate endothelial nitric-oxide synthase expression. J Pharmacol Exp Ther. 2000;292:606-609.
13. Verhaar MC, Honing ML, van Dam T, et al. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res. 1999;42:752-760.
14. Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1β induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest. 1996;97:769-776.
15. Fukumoto Y, Shimokawa H, Kozai T, et al. Tyrosine kinase inhibitor suppresses the (re)stenotic changes of the coronary artery after balloon injury in pigs. Cardiovasc Res. 1996;32:1131-1140.
16. Takemoto M, Sun J, Hiroki J, et al. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 2002; 106:57-62.
17. Flavahan NA, Vanhoutte PM. G-proteins and endothelial responses. Blood Vessels. 1990;27:218-229.
18. Shimokawa H, Nakaike R, Takeshita A. Significance of defective endothelial signal transduction in impaired endothelium-dependent relaxation in atherosclerosis. Gerontology. 1995;41(Suppl 1):28-33.
19. Shimokawa H, Lam JY, Chesebro JH, et al. Effects of dietary supplementation with cod-liver oil on endothelium-dependent responses in porcine coronary arteries. Circulation. 1987;76:898-905.
20. Shimokawa H, Vanhoutte PM. Dietary cod-liver oil improves endothelium-dependent responses in hypercholesterolemic and atherosclerotic porcine coronary arteries. Circulation. 1988;78:1421-1430.
21. Tagawa H, Shimokawa H, Tagawa T, et al. Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease. J Cardiovasc Pharmacol. 1999;33:633-640.
22. Shimokawa H. Beneficial effects of eicosapentaenoic acid on endothelial vasodilator functions in animals and humans. World Rev Nutr Diet. 2001; 88:100-108.
23. Aikawa M, Sugiyama S, Hill CC, et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation. 2002;106:1390-1396.
24. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273: 24266-24271.
25. Mitai S, Zhang X, Zhao G, et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol. 2000;279:H2649-H2657.
26. Amin-Hanjani S, Stagliano NE, Yamada M, et al. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001;32:980-986.
27. Ding Y, Vaziri ND. Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells. Hypertension. 1998;32: 718-723.
28. Yamashita T, Kawashima S, Ozaki M, et al. A calcium channel blocker, benidipine, inhibits intimai thickening in the carotid artery of mice by increasing nitric oxide production. J Hypertens. 2001;19:451-458.
29. 495. Cardiovasc Res. 2003;59:844-853.
30. Jukema JW, Zwinderman AH, van Boven AJ, et al. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Arterioscler Thromb Vasc Biol. 1996;16:425-430.
31. van de Poll SW, Delsing DJ, Wouter Jukema J, et al. Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice. J Mol Cell Cardiol. 2003;35:109-118.
32. Delsing DJ, Jukema JW, van de Wiel MA, et al. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. J Cardiovasc Pharmacol. 2003;42:63-70.
33. Orekhov AN, Tertov VV, Sobenin IA, et al. Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin. Int J Cardiol. 1997;62(Suppl 2):S67-S77.
34. Leibovitz E, Beniashvili M, Zimlichman R, et al. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens. 2003;16:715-718.
35. Fogari R, Derosa G, Lazzari P, et al. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens. 2004;17:823-827.
36. The ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation. 2003;107:422-428.
37. Luscher TF. ENCORE II. The long-term effect of nifedipine on vasomotion and vessel morphology in patients with coronary artery disease: an intravascular ultrasound-assisted evaluation. ESC Congress. 2004;Hot Line Program No. 102.